

GP/1648/13
#13
Elec. w/Seq.
2/20/02
ATTORNEY DOCKET NO. 01123.0004
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

In re application of)

Rubin et al.)

Serial No.: 09/509,712)

Filed: March 31, 2000)

For: MAMMALIAN GENES INVOLVED IN)
VIRAL INFECTION AND TUMOR)
SUPPRESSION)

Group Art Unit: 1648

Examiner: Foley, S.

COPY OF PAPERS
ORIGINALLY FILED

ELECTION UNDER RESTRICTION REQUIREMENT AND RESPONSE TO NOTICE TO
COMPLY WITH APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID DISCLOSURES

Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

January 23, 2002

Sir:

Seq. list placed before
This is in response to the Office Action dated November 23, 2001 wherein restriction of the claims of the above-identified application is required. A Request for Extension of Time is included herewith.

The Office has acknowledged applicants' election of Group IV, claims 24 and 30, which included an election of 10 sequences for examination. However, the Office Action states that applicant is to further elect a single sequence for examination.

ATTORNEY DOCKET NO. 01123.0004
Serial No. 09/509,712

Applicants provisionally elect SEQ ID NO: 75 for examination. Claim 24 and 30 are readable on the elected species. Applicants acknowledge that, upon allowance of a generic claim, applicants will be entitled to consideration of claims to additional species.

In response to the November 23, 2001 Communication and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued regarding the above-identified patent application. A copy of each of these documents is enclosed.

As suggested in the Raw Sequence Listing Error Report, sequences 1-127 have been corrected to include the mandatory "<220> feature" and associated headings. Typographical errors in the original Sequence Listing have also been corrected. Thus, no new matter is introduced by the corrected Sequence Listing.

Enclosed herewith is a diskette containing the corrected Sequence Listing for this application in computer readable form (CRF) and a paper copy of the corrected Sequence Listing in compliance with 37 C.F.R. §§ 1.821-1.825. Applicants hereby certify that the information in the computer readable form on the diskette and in the hard copy of the Sequence Listing enclosed herewith is the same and includes no new matter.

The enclosed computer readable copy and paper copy of the Sequence Listing are believed to bring the Sequence Listing into full compliance with the sequence rules. Therefore, entry of the Sequence Listing is respectfully requested.


ATTORNEY DOCKET NO. 01123.0004

Serial No. 09/509,712

Payment in the amount of \$55.00 (extension of time fee) is to be charged to a credit card and such payment is authorized by the signed, enclosed document entitled Credit Card Payment Form PTO-2038. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.



Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date shown below.



Gwendolyn D. Spratt

1-23-02

Date